At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 17, 2026 at 16:05 ET
Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-dependent tumor growth inhibition and synergistic anti-tumor activity when combined with anti-PD-1 therapy in an immunotherapy-refractory head and neck cancer model. These findings support ongoing clinical trials of MICVO as monotherapy and in combination with pembrolizumab for recurrent/metastatic HNSCC.
- Preclinical data show maMICVO monotherapy inhibited tumor outgrowth in a syngeneic HNSCC model in a dose-dependent manner, with 6 mg/kg showing strongest effect
- Combination of maMICVO and anti-mouse PD-1 showed synergistic anti-tumor activity in an immunotherapy-refractory model, with greater tumor control than either agent alone
- maMICVO modulated the tumor immune environment by reducing regulatory T cells (Tregs), increasing CD8+ T cell-to-Treg ratio, and enhancing progenitor exhausted T cells responsive to anti-PD-1
- Data to be presented at AACR 2026; supports ongoing Phase 1/2 trials of MICVO alone and with pembrolizumab in R/M HNSCC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access